Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in …
Biotechnology
US, San Carlos [HQ]
Balance Sheet
6 Sheets · Starting from 2018In Million USD. Margins, Growth Rates In %
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Assets | 70.00 | 65.00 | 392.00 | 324.00 | 1,006.00 | 1,407.00 | |
|
Current
|
66.00 | 61.00 | 389.00 | 256.00 | 942.00 | 1,095.00 | |
| Cash And Equivalents | 66.00 | 58.00 | 386.00 | 68.00 | 834.00 | 397.00 | |
| Assets | 70.00 | 65.00 | 392.00 | 324.00 | 1,006.00 | 1,407.00 | |
| Accounts Receivables (AR) | 1.00 | - - | - - | - - | - - | - - | |
| Inventory | - - | - - | - - | -1.00 | -1.00 | - - | |
| Short Term Investments | - - | - - | - - | 176.00 | 96.00 | 682.00 | |
| Other Current Assets | - - | 2.00 | 2.00 | 10.00 | 11.00 | 12.00 | |
|
Non Current
|
4.00 | 3.00 | 3.00 | 67.00 | 63.00 | 311.00 | |
| Property, Plant, Equipment (Net) | 3.00 | 3.00 | 3.00 | 35.00 | 31.00 | 110.00 | |
|
Intangible Assets
|
- - | - - | - - | - - | - - | - - | |
| Goodwill | - - | - - | - - | - - | - - | - - | |
| Long Term Investments | - - | - - | - - | 27.00 | 26.00 | 163.00 | |
| Other Non Current Assets | - - | - - | - - | 4.00 | 5.00 | 37.00 | |
| Liabilities | 128.00 | 172.00 | 46.00 | 40.00 | 52.00 | 167.00 | |
|
Current
|
6.00 | 11.00 | 46.00 | 28.00 | 40.00 | 145.00 | |
| Accounts Payable | 1.00 | - - | 26.00 | -12.00 | 2.00 | 11.00 | |
| Short Term Debt | - - | - - | - - | 5.00 | 5.00 | 7.00 | |
| Deferred Revenue | - - | - - | - - | - - | - - | - - | |
| Tax Payable | - - | - - | - - | - - | - - | - - | |
| Other Current Liabilities | 3.00 | 7.00 | 17.00 | 16.00 | 24.00 | 123.00 | |
|
Non Current
|
121.00 | 161.00 | - - | 11.00 | 12.00 | 22.00 | |
| Long Term Debt | - - | - - | - - | 11.00 | 12.00 | 22.00 | |
| Leasing Obligations | - - | - - | - - | 16.00 | 17.00 | 22.00 | |
| Deferred Non Current Tax Liabilities | - - | - - | - - | - - | - - | - - | |
| Other Non Current Liabilities | 121.00 | 161.00 | - - | - - | - - | - - | |
| Equity | -57.00 | -106.00 | 345.00 | 284.00 | 953.00 | 1,240.00 | |
| Stockholders' Equity | -57.00 | -106.00 | 345.00 | 284.00 | 953.00 | 1,240.00 | |
| Retained Earnings | -59.00 | -109.00 | -198.00 | -298.00 | -522.00 | -924.00 | |
| Common Stock | - - | - - | - - | - - | - - | - - | |
| Preferred Stock | - - | 160.00 | 392.00 | 324.00 | - - | - - | |
| Profit | -29.00 | -53.00 | -87.00 | -100.00 | -239.00 | -402.00 | |
| Dividends | - - | - - | - - | - - | - - | - - | |
| Minority Interest | - - | - - | - - | - - | - - | - - | |
| Other Stockholders' Equity | 3.00 | 2.00 | 544.00 | 258.00 | 1,476.00 | 2,164.00 | |
| Loss Other Compr. Income | -1.00 | -160.00 | -392.00 | - - | - - | - - |